Beyond that, there are references to higher percentages of stable disease or progression to standard chemotherapy in patients with KRAS-mutated colorectal tumors (81% versus 62% for the KRAS wild-type group) [46]. This evidence concerns the gene KRAS and colorectal neoplasm.